← All trials
NCT04201496
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 16, 2019
- Primary completion
- Apr 30, 2020
- Completion date
- Apr 30, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 40
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of VirginiaLead sponsor
- University of VirginiaStudy chair
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Collaborator
- University of VirginiaOverall official - principal investigator
- University of VirginiaSponsor investigator
- DexCom, Inc.Collaborator
- Tandem Diabetes Care, Inc.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.